Skip to navigation Skip to content

Chronic pouchitis Program in Pharmaceutical Benefits Scheme (PBS) 012-24110514

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised vedolizumab for patients with moderate to severe chronic pouchitis.

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Chronic pouchitis quick reference

Note: In Processing and National Demand Allocation (PaNDA) WorkLoad Management (WLM) system, work items for Pouchitis (POUCH) have been merged with Ulcerative Colitis (UC) in Health Professional Online Services (HPOS) and Written (WRIT) folders respectively.

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

or

Recommencement after a break

PB379 form

Written

S100:

vedolizumab i.v.

No

OPA

Must be treated by a:

  • gastroenterologist
  • consultant physician (internal medicine specialising in gastroenterology)
  • consultant physician (general medicine specialising in gastroenterology)

No

Grandfather

PB380 form

Written

S100:

vedolizumab i.v.

No

OPA

Must be treated by a:

  • gastroenterologist
  • consultant physician (internal medicine specialising in gastroenterology)
  • consultant physician (general medicine specialising in gastroenterology)

No

Continuing

Telephone

Electronic

S100:

vedolizumab i.v.

No

OPA

Must be treated by a:

  • gastroenterologist
  • consultant physician (internal medicine specialising in gastroenterology)
  • consultant physician (general medicine specialising in gastroenterology)

Yes

Balance of supply

Telephone

Electronic

S100:

vedolizumab i.v.

No

OPA

Must be treated by a:

  • gastroenterologist
  • consultant physician (internal medicine specialising in gastroenterology)
  • consultant physician (general medicine specialising in gastroenterology)

Yes